Efficacy and Safety of Topical Timolol Eye Drops in the Treatment of Myopic Regression after Laser In Situ Keratomileusis: A Systematic Review and Meta-Analysis

Table 2

Clinical characteristics of eligible studies.

Study; (year)	Study design	Conc. of timolol (%)	Timolol regimen and duration	Follow-up	⁢Mean pre-LASIK SE ± SD,; diopters		⁢Mean pre-LASIK IOP,; mmHg
					Timolol	Control	Timolol	Control
Zhongwen 2014 [13]	Prospective	0.5	Twice a day for 1 mo	1 wk/1 mo/; 3 mo/6 mo	−7.00 ± 0.77	−7.32 ± 1.10	16.33 ± 2.69	16.90 ± 3.00
Guan 2013 [14]	NS	0.5	Twice a day for 3 mo	3 mo	−5.85 ± 2.52	−5.64 ± 2.31	14.65 ± 2.35	15.45±2.13
Shojaei et al. 2012 [15]	Prospective	0.5	Twice a day for 6 mo	3 mo/6 mo/; 12 mo	−8.10 ± 3.41	−4.87 ± 1.88	12.73 ± 1.43	12.38 ± 1.65
Zhang et al. 2011 [16]	Prospective	0.5	Twice a day for 1 mo	1 wk/1 mo/; 3 mo	−4.94 ± 1.09	24.53 ± 2.31	15.22 ± 1.78	15.11 ± 2.53
Yang et al. 2010 [17]	NS	0.025	Twice a day for 2 wk	2 wk	−7.01 ± 3.04	−6.53 ± 2.40	NS	NS
EI-Awady et al. 2010 [18]	Prospective	0.1	Once a day for 12 mo	12 mo	NS	NS	NS	NS

SD: standard deviation; Yr: years; mo: months; wk: weeks; Conc.: concentration; NS: data not available.